The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The metabolic activity assessed by 18F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.
 
Jeesun Yoon
No Relationships to Disclose
 
Hyunpil Sung
No Relationships to Disclose
 
Kyung-Hun Lee
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Dae-Won Lee
No Relationships to Disclose
 
Tae-Yong Kim
No Relationships to Disclose
 
Ju-Hee Bang
No Relationships to Disclose
 
Ah-Rong Nam
No Relationships to Disclose
 
Kyoung-Seok Oh
No Relationships to Disclose
 
Jae-Min Kim
No Relationships to Disclose
 
Yoojin Jeong
No Relationships to Disclose
 
Sea Young Choo
No Relationships to Disclose
 
Hyo Jung Kim
No Relationships to Disclose
 
Su In Lee
No Relationships to Disclose
 
Gi Jeong Cheon
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER